Jan. 23 at 7:50 PM
RBC Capital⬆️the PT on
$GHRS to
$40 from
$33, reiterated at Outperform and said, Raising Price Target to
$40 Following Psychedelics Symposium and Reiterating Outperform
$JNJ $HELP ATAI CYBN MNMD CMPS
RBC Capital additionally said:
Following our Psychedelics Symposium and discussions with mgmt., payers, and docs, we are increasingly optimistic on GHRS's long-term sales opportunity with GH001 and are raising our price target to
$40 from
$33 based on updated assumptions about drug pricing in-line with Spravato.
With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains a high quality mid-stage story in the emerging psychedelics space.
